ArticleJournal of clinical biochemistry and nutrition2025
FOXM1 transcriptionally activates NEIL3 to inhibit ferroptosis in lung adenocarcinoma cells.
Article in Journal of clinical biochemistry and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Regulatory Network of FOXM1: Orchestrating Cancer Progression and Resistance to Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) is responsible for a substantial portion of cancer-related deaths, carrying a bleak treatment outlook. The application of ferroptosis-focused treatments has shown great potential. This research is committed to uncovering the molecular mechanisms by which Nei Like DNA Glycosylase 3 (NEIL3) impacts ferroptosis in LUAD, in the quest for robust biomarkers. Using The Cancer Genome Atlas database, qRT-PCR, and Western blot (WB), we evaluated the expression of NEIL3 in LUAD tissues and cells, then performed gene set enrichment analysis to identify enriched gene sets. Predictive tools hTFtarget and MoLoTool assisted in identifying potential upstream transcription factors and their promoter binding sites for NEIL3, following which we conducted Pearson correlation analysis. The binding affinity of NEIL3 to Forkhead box protein M1 (FOXM1) was validated with dual-luciferase and chromatin immunoprecipitation assays. Cell viability was determined by measuring MDA and Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.